Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04516291 · ClinicalTrials.gov registry record · Phase 2
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
NCT04516291 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 286 participants.
The verdict
NCT04516291, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
Study Summary
This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557 (hereafter, vupanorsen) administered subcutaneously (SC) at various doses and regimens in participants with dyslipidemia, defined in this study as participants with elevated non-HDL-C and TG who are receiving a stable dose of a statin. This study is also known as TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in AdulTs with dyslipidEmia (TRANSLATE-TIMI 70).
Interventions
- DRUG Placebo
- DRUG Vupanorsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2021-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04516291
The ClinicalTrials.gov registry entry for NCT04516291 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 286 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04516291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04516291 about?
NCT04516291 is a clinical study titled "A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)". This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557 (hereafter, vupanorsen) administered subcutaneously (SC) at various doses and regimens in participants with dyslipidemia...
What is the current status of trial NCT04516291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2020-09-28. Estimated completion is 2021-12-06.
What interventions are being tested in trial NCT04516291?
The interventions under investigation include: Placebo (DRUG), Vupanorsen (DRUG).
Who is sponsoring clinical trial NCT04516291?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.